Bcl-2 inhibitors developed by Baiji Shenzhou were declared clinically and accepted in China.

Screenshot source: CDE official website BGB-11417 is a Bcl-2 inhibitor developed by Baiji Shenzhou, with high selectivity.
in some blood cancers and other tumor types, the accumulation of Bcl-2 proteins can prevent tumor cells from entering the apoptosis process.
Bcl-2 inhibitors can kill tumors by selectively inhibiting the Bcl-2 protein to restore the mechanism of procedural death (apoptosis) of tumor cells.
BGB-11417 is a potential "best-in-class" new drug that has demonstrated anti-tumor activity in blood tumor models and has some potential advantages, including: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . The selectivity of Bcl-2 is higher than that of Bcl-xL; in animal GLP toxicology studies, NOAEL (no level of harmful effects observed) exposure was nearly 30 times higher than expected for human therapy;
BGB-11417 is currently conducting a phase 1a/1b open label, dose increment and expansion study in Australia for patients with mature B-cell malignancies, according to the Website of the Website.
116 subjects in the study program, which officially began in March this year, and are currently being recruited.
, the company plans to develop the BGB-11417 as a single drug and as a joint BTK inhibitor Zebtinib, according to baiji Shenzhou.
, previous studies have provided the basis for a combined use of Bcl-2 inhibitors and BTK inhibitors.
Based on data from a two-part one-arm study published in the New England Journal of Medicine (NEJM) in 2019, 25 of the 26 assessable patients received CR/CRi and a CR/CRi rate of 96 percent over 18 months of the first-line treatment of chronic lymphoblastic leukemia with the BTK inhibitor Ibteni.
this exceeds the clinical data of any previous treatment option and gives great confidence in the development of a combination of Bcl-2 inhibitors and BTK inhibitors.
it is worth mentioning that, in addition to targeting malignant tumors in the blood system, Bcl-2 inhibitors are also expected to be effective in solid tumors, especially as an effective treatment strategy for breast cancer and small cell lung cancer.
also means that the BGB-11417 will have wider treatment prospects.
hope that the Bcl-2 inhibitor BGB-11417 in Baiji Shenzhou will progress smoothly in the follow-up clinical development and make new breakthroughs at an early time, so as to benefit more patients.
source: Medical Mission Hills.